Genomics in medicine and public health: Role of cost-effectiveness analysis

JAMA

Volumn 286, Issue 13, 2001, Pages 1637-1638

  Goldie, Sue J ^a   Levin, April R ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; GENOME; HEALTH ECONOMICS; HUMAN; MEDICAL GENETICS; PREVENTIVE HEALTH SERVICE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PUBLIC HEALTH; SHORT SURVEY; ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; GENETIC DISORDER; GENETIC PREDISPOSITION; GENETIC SCREENING;

COST-BENEFIT ANALYSIS; GENETIC DISEASES, INBORN; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; PREVENTIVE MEDICINE;

EID: 85047681336     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.13.1637-JMS1003-5-1     Document Type: Short Survey

References (8)

1. Shattuck lecture - Medical and societal consequences of the human genome project
2. Will genetics revolutionize medicine?
3. If I had a gene test, what would I have and who would I tell?
4. The use of gene tests to detect hereditary predisposition to cancer: Economic considerations
5. Assessing the cost-effectiveness of pharmacogenomics
6. Common hereditary cancers and implications for primary care
7. Use of genotypic resistance testing to guide HIV therapy: Clinical impact and cost-effectiveness